Three Key Updates in HIV Treatment: EACS Guidelines
The latest EACS HIV treatment recommendations bring three important changes: a broader eligibility for dolutegravir/lamivudine, a revised approach to the historical M184V resistance mutation, and expanded consideration of long-acting injectable therapy for selected patients who have not achieved viral suppression.
12 november 2026 07:49
New HIV Antibody Treatment Shows Promise — But Who Would Benefit Most?
Could long-acting antibody treatment make HIV care easier for older adults? New findings presented at HIV Drug Therapy Glasgow 2026 suggest potential benefits for people managing multiple medications. But with only 20 participants and 24 weeks of follow-up, ...
Lugege edasi
11 november 2026 10:00
How Switzerland Prevented Hundreds of HIV Diagnoses With PrEP — and Who Is Still Being Left Behind
Switzerland’s national PrEP strategy may have helped avert an estimated 268 HIV diagnoses, according to findings presented at HIV Drug Therapy Glasgow 2026. But the benefits remain unevenly distributed: women account for just 1–2% of PrEP users, highlighting ...
Lugege edasi
Mis on Life4me+?
Üks Life4me+ peamiseid eesmärke on uute HIVi- ja muude sugulisel teel levivate nakkuste juhtumite, nagu ka C-hepatiiti ja tuberkuloosi nakatumise ennetamine. Seepärast räägime HIVist ja muudest haigustest — sellest, kuidas end nende eest kaitsta ja kuidas elada nakatununa.
Rohkem
Kampaania Life4me+
Info haridusliku kampaania "M = M" kohta ("Mittetuvastatav = mitteedasikanduv", #UequalsU, #НравноН), mis on Life4me+ poolt organiseeritud Ida-Euroopas ja Kesk-Aasias regioonis, suunatud info levitamisele, et HIV-positiivne inimene mittetuvastatava viiruskoormusega ei saa viirust seksuaalsel teel edasi kanda teisele inimesele.
Mitmed uuringud on näidanud, et diskordantses paaris, kus HIV-positiive partner võtab ARV ravimeid ja hoiab viiruskoormuse mittetuvastataval tasemel, ei ole teada juhtumitest, kus HIV oleks seksuaalsel teel edasi kandunud.
Meie partnerid
